Rituxan
Payments companies reported to CMS as associated with Rituxan. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Rituxan, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Rituxan
These are the largest totals companies reported as associated with Rituxan. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Seema Bhat | Columbus, OH | Hematology (Internal Medicine) | $5,116.71 |
| Susan O Brien | Orange, CA | Medical Oncology | $3,922.42 |
| John Burke | Aurora, CO | Hematology & Oncology | $3,610.00 |
| Deborah Stephens | Salt Lake City, UT | Hematology (Internal Medicine) | $3,599.08 |
| Bita Fakhri | Palo Alto, CA | Hematology (Internal Medicine) | $3,553.63 |
| Jacqueline Barrientos | Miami Beach, FL | Hematology & Oncology | $3,331.78 |
| Catherine Coombs | Orange, CA | Hematology & Oncology | $3,300.28 |
| Shuo Ma | Chicago, IL | Hematology & Oncology | $3,165.67 |
| Emily Tomasulo | Philadelphia, PA | Hematology & Oncology | $3,016.87 |
| Shazia Nakhoda | Philadelphia, PA | Hematology & Oncology | $2,994.12 |
Prescribed Rituxan?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.